...
首页> 外文期刊>Pharmaceutical development and technology >Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
【24h】

Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.

机译:结合坎地沙坦纳米颗粒的固体口服剂型的开发和表征。

获取原文
获取原文并翻译 | 示例
           

摘要

Sparingly water-soluble drugs such as candesartan cilexetil offer challenges in developing a drug product with adequate bioavailability. The objective of the present study was to develop a tablet dosage form of candesartan cilexetil incorporating drug nanoparticles to increase its saturation solubility and dissolution rate for enhancing bioavailability while reducing variability in systemic exposure. The bioavailability of candesartan cilexetil is dissolution limited following oral administration. To enhance bioavailability and overcome variability in systemic exposure, a nanoparticle formulation of candesartan cilexetil was developed. Candesartan cilexetil nanoparticles were prepared using a wet bead milling technique. The milled nanosuspension was converted into solid intermediate using a spray drying process. The nanosuspensions were characterized for particle size before and after spray drying. The spray dried nanoparticles were blended with excipients for tableting. The saturation solubility and dissolution characteristics of the nanoparticle formulation were investigated and compared with commercial candesartan cilexetil formulation. The drug nanoparticles were evaluated for solid-state transitions before and after milling. This study demonstrated that tablet formulation incorporating drug nanoparticles showed significantly faster rate of drug dissolution in a discriminating dissolution medium as compared to commercially available tablet formulation. Systemic exposure studies in rats indicated a significant increase in the rate and extent of drug absorption.
机译:难溶于水的药物(例如坎地沙坦西酯)在开发具有足够生物利用度的药物产品方面面临挑战。本研究的目的是开发一种坎地沙坦酯片状剂型,其掺入药物纳米颗粒以增加其饱和溶解度和溶出度,从而提高生物利用度,同时减少全身暴露的变异性。口服后坎地沙坦酯的生物利用度受到限制。为了提高生物利用度并克服全身性暴露的变异性,开发了坎地沙坦酯的纳米颗粒制剂。使用湿珠磨技术制备坎地沙坦酯。使用喷雾干燥工艺将研磨的纳米悬浮液转化为固体中间体。在喷雾干燥之前和之后表征纳米悬浮液的粒度。将喷雾干燥的纳米颗粒与赋形剂混合用于压片。研究了纳米颗粒制剂的饱和溶解度和溶解特性,并将其与市售坎地沙坦西酯制剂进行了比较。在研磨之前和之后评估药物纳米颗粒的固态转变。这项研究表明,与市售片剂制剂相比,掺入药物纳米颗粒的片剂制剂在明显的溶出介质中显示出明显更快的药物溶出速率。在大鼠中进行的全身暴露研究表明,药物吸收的速率和程度显着增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号